FDA approves Botox (Allergan) as a treatment for Overactive Bladder

The FDA on 18 January 2013 expanded the approved use of Botox (onabotulinumtoxinA) from Allergan, to treat adults with Overactive Bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.

When Botox is injected into the bladder muscle, it causes the bladder to relax, increasing the bladder�s storage capacity and reducing episodes of urinary incontinence. Injecting the bladder with Botox is performed using cystoscopy, a procedure that allows a doctor to visualize the interior of the bladder while Botox is being injected.